Analog design is usually defined as the modification of a drug molecule or of any bioactive compound in order to prepare a new molecule showing chemical and biological similarity with the original model compound

1. ANALOG DESIGN
Presented by,
Komal Bajaj
Mohit Umare
M. Pharm First Year (2019-20)
Department of Pharmceutical Sciences RTM Nagpur University,
Nagpur.440033
1

2. CONTENTS
• INTRODUCTION
• BIOISOSTERIC REPLACEMENT
• RIGID ANALOG
• ALTERATION OF CHAIN BRANCHING
• CHANGE IN RING SIZE
• RING POSITION ISOMERS
• STEREO ISOMERS
• GEOMERTRIC ISOMERS
• FRAGMENTS OF THE LEAD MOLECULE
• VARIATION IN INTERATOMIC DISTANCES
• REFERENCES
2

3. INTRODUCTION
Definition
• Analog design is usually defined as the
modification of a drug molecule or of any
bioactive compound in order to prepare a new
molecule showing chemical and biological
similarity with the original model compound
3

4. GOALS OF ANALOG DESIGN
• To modify the chemical structure of the lead com-
pound to retain or to reinforce the desirable
pharmacologic effect while minimizing un-
wanted pharmacological , physical and chemical
properties, which may result in a superior
therapeutic agent.
• To use target analogs as pharmacological probes
to gain better insight into the pharmacology of
the lead molecule and perhaps to reveal new
knowledge of basic biology.
4

5. CATEGORIES OF ANALOGS
1] Analogs possessing chemical and
pharmacological similarities:
• The first class of analogs, simultaneously having
chemical and pharmacological similarities, can
be considered as “directanalogs” .
• These analogs correspond to the category of
drugs often referred to as“metoodrugs”.
• Usually,they are an advantage to the consumer
.In the case of drugs, this means that they
provide an advance in therapeutic benefit.
5

6. CATEGORIES OF ANALOGS
2] Analogs possessing only chemical
similarities:
• The second class, made of “structural analogs,”
contains compounds originally prepared as close
and patentable analogs of a novel lead, but for
which the biological assays revealed totally
unexpected pharmacological properties.
• Observation of the new activity can be purely by
chance but can also result from a planned
systematic investigation.
6

7. CATEGORIES OF ANALOGS
3] Compounds chemically different, but
displaying similar pharmacological
properties:
• Third class of analogs, chemical similarity is not
observed; however, they share common
biological properties.
• We propose the term “functional analogs” for
such compounds.
7

8. Strategies for molecular modification
of the lead compound
1. Bioisosteric replacement.
2. Design of rigid analogs.
3. Homologation of alkyl chain(s) or alteration of chain
branching, design of aromatic ring-position isomers,
alteration of ring size, and substitution of an aromatic
ring for a saturated one, or the converse.
4. Alteration of stereochemistry, or design of geometric
isomers or stereoisomers.
5. Design of fragments of the lead molecule that contain
the pharmacophoric group (bond disconnection).
6. Alteration of interatomic distances within the
pharmacophoric group or in other parts of the molecule.
8

9. 1] BIOISOSTERIC REPLACEMENT
• Bioisosteres are groups or molecules which
have chemical and physical properties
producing broadly similar biological properties
• This definition might be modified to include
the concept that bioisosteres may produce
opposite biological effects, and these effects
are frequently a reflection of some action on
the same biological process or at the same
receptor site.
9

10. 1] BIOISOSTERIC REPLACEMENT
Utility of bioisosteres :
• Improving potency
• Enhancing selectivity
• Altering physical properties
• Reducing or redirecting metabolism
• Eliminating or modifying toxicophores
• Acquiring novel intellectual property
10

11. 1] BIOISOSTERIC REPLACEMENT
Classification:
Bioisosteres have been classified into classical
and non-classical bioisosteres.
Bioisosteres
Classical
Same stearic and
electronic properties
Non-
classical
Different stearic and
electronic properties
11

12. 1] BIOISOSTERIC REPLACEMENT
Classical Bioisoster :
• Monovalent atoms or groups.
• Divalent atoms or groups.
• Trivalent atoms or groups.
• Tetra substituted atoms.
• Ring equivalents.
12

13. 1] BIOISOSTERIC REPLACEMENT
13
Monovalent atoms or groups.
D and H
F and H
NH2 and OH
RSH and ROH
F, OH ,NH2, and CH3
CL , Br , SH ,and OH
Fig. Bioisoisteric H/F Replacement

14. 1] BIOISOSTERIC REPLACEMENT
Divalent atoms or groups.
-C=S- ,-C=O,-C=NH, -C=C-
Procainamide Procaine
14
Cardiac arrhythmia Local anesthetic

15. 1] BIOISOSTERIC REPLACEMENT
• Trivalent atoms or groups.
-CH= , -N= , -P= , –As=
Fig. Cholesterol and it’s biosteric derivative 20,25-diazacholeserol
15

16. 1] BIOISOSTERIC REPLACEMENT
• Tetra substituted atoms.
16

17. 1] BIOISOSTERIC REPLACEMENT
• Ring equivalents :
-CH=CH-,-S-(e.g.benzene,thiophene)
=CH-,=N-(e.g.benzene,pyridine)
-O-,-S-,-NH-
17

18. 1] BIOISOSTERIC REPLACEMENT
Non classical bioisosters:
• Cyclic vs Non Cyclic
• Exchangable Functional groups
18

19. 1] BIOISOSTERIC REPLACEMENT
Cyclic vs Non Cyclic
Fig. Replacement of a cyclic system with an acyclic derivative from
estradiol to trans-diethylstilbestrol.
19

20. 1] BIOISOSTERIC REPLACEMENT
Exchangable Functional groups:
i)Carbonyl group
20

21. 1] BIOISOSTERIC REPLACEMENT
21
Modafinyl Carbonyl analog Amide analog
Slight loss of activity Activity restored
Fig. Bioisosteric replacement of modafinil

22. 1] BIOISOSTERIC REPLACEMENT
ii) Catecol group:
22

23. 1] BIOISOSTERIC REPLACEMENT
iii)Thiourea group:
23
Fig. Thioamide bioisosteric replacement
Cyano imino group

24. 1] BIOISOSTERIC REPLACEMENT
iv)Carboxylic Acid :
24

25. 1] BIOISOSTERIC REPLACEMENT
v)Hydroxyl Group:
25
vi)Halogen :

26. 1] BIOISOSTERIC REPLACEMENT
vii)Pyridine :
26

27. 2] RIGID ANALOG
Imposition of some degree of molecular rigidity
on a flexible organic molecule may result in
potent, biologically active agents that show a
higher degree of specificity of pharmacologic
effect.
27

28. 2] RIGID ANALOG
Advantages:
• The key functional groups are held in one steric
disposition.
• By the rigid analog strategy, it is possible to
approximate "frozen" conformations of a
flexible lead molecule that, if an enhanced
pharmacological effect results, may assist in
defining and understanding structure activity
parameters, including the three dimensional
geometry of the pharmacophore.
28

29. 2] RIGID ANALOG
29
• Restriction of conformational freedom of the acyl moiety in 4-DAMP
(Diphenylacetoxypiperidinium ) an antimuscarinic compound displaying
higher affinity at M3, acetylcholine receptors than at atrial M2, receptors was
imposed by the structure of the spiro-compound.
• Spiro-DAMP was slightly more potent at M2, muscarinic receptors than at
M3, receptors.

30. 3] ALTERATION OF CHAIN BRANCHING
• Change in size or branching of an alkyl chain on a
bioactive molecule may have profound (and sometimes
unpredictable) effects on physical and pharmacological
properties.
• Alteration of the size and or shape of an alkyl substituent
can affect the conformational preference of a flexible
molecule and may alter the relationships of the
components of the pharmacophore, which may be reflected
in the ability of the molecule to achieve complementarity
with its receptor or with the catalytic surface of a
metabolizing enzyme.
• The alkyl group itself may represent a binding site with
the receptor (through hydrophobic interactions), and
alteration of the chain may alter its binding capacity.
30

31. 3] ALTERATION OF CHAIN BRANCHING
31
• Alteration in N-alkyl chain in norapomorphine from methyl to n-
propyl produced incremental increase in emetic response.
• n-butyl homolog demostrated a tremendous loss in potency and
activity .

32. 4] CHANGE IN RING SIZE
• In a series of spiro-tetraoxacycloalkanes,with varying
heterocyclic ring sizes, it was found that the compound where
n = 1 demonstrated marked antimalarial activity against P.
bergei and P. falciparum, and showed low toxicity.
• The analog in which n = 4 showed strong activity against P.
falciparum but it was unimpressive in the P. bergei assay.
32

33. 5] RING POSITION ISOMERS
• Positional isomers are constitutional Isomers
that have the same carbon skeleton and the
same functional group but differ from each
other in the location of the functional
groups on or in the carbon chain.
• Position isomers of substituents (even alkyl
groups) on an aromatic ring may possess
different pharmacological properties.
33

34. 5] RING POSITION ISOMERS
In a series of arylsulfonamidophenethanolamines ,
derivatives bearing the sulfonamido group meta to the
ethanolamine side chain displayed properties of a β-
adrenoceptor partial agonist, whereas 19
compounds bearing the sulfonamido group in the para
position were β-antagonists.
34

35. 6] STEREO ISOMERS
• Stereoisomers are molecules that have the
same molecular formula and differ only in
how their atoms are arranged in three-
dimensional space.
• All stereoisomers of an organic molecule will
exhibit pharmacological effects, frequently
widely different and unpredictable.
35

36. 6] STEREO ISOMERS
36
(+-)3-(3-Hydroxypheny1)-
N-n-propylpiperidine
R enantiomer: At high doses
selectively stimulated
presynaptic dopaminergic
receptor sites,
whereas at lower doses it
selectively stimulated
postsynaptic receptor sites.
S enantiomer: stimulated
presynaptic dopamine receptors
and at the same dose level, it
blocked postsynaptic dopamine
receptors.

37. 7] GEOMERTRIC ISOMERS
• Geometric isomers are molecules in which
each of two or more chemical compounds having
the same molecular formula but a different
geometric arrangement;an unsaturated
compound or ring compound in which rotation
around a carbon bond is restricted, as in cis- and
trans- configurations.
• cis- and trans-4-Aminocrotonic acid and
were prepared as congeners of Gama
aminobutyric acid (GABA).
37

38. • The folded 2-isomer was inactive in assays
for GABA agonism, whereas the ex- tended
E-isomer was active.
• These data demonstrate biological differences
of geometric isomers.
38
7] GEOMERTRIC ISOMERS

39. • Lead molecules present in polycyclic natural
products may be much more structurally complex
than in necessary for optimal pharmacological
effect.
• Pharmacophoric moiety may be buried within the
complex structure of the lead compound.
• This pharmacophore can be dissect out chemically.
• The result may be biologically active, simpler
molecules that may themselves be used as leads in
further analog design.
39
8] FRAGMENTS OF THE LEAD
MOLECULE

40. • STRATEGY
A bond disconnection strategy may be employed
in which bonds in the polycyclic structure are
broken or removed to destroy one or more of the
rings.
40
8] FRAGMENTS OF THE LEAD
MOLECULE
Example :Morphine as a lead molecule for
which fragment analog design has been
used.
Morphine

41. Fragmented Analogs:
41
8] FRAGMENTS OF THE LEAD
MOLECULE
Levophanol metazocine meperidine
methadone

42. Alteration of distances between portions of
the pharmacophore of a molecule (or even
between other portions of the molecule) may
produce profound qualitative and/or quantitative
changes in pharmacological actions.
42
9] VARIATION IN INTERATOMIC
DISTANCES

43. • In bis-trimethylammonium
polymethylene
Compounds showing autonomic ganglia blocking
acvtivity .
43
9] VARIATION IN INTERATOMIC
DISTANCES
n=5 or 6 maximum activity
n= 4 or 7 effect drops drastically
n= 16 0r 18 4x more potent

44. REFERENCES
44
• Burger's Medicinal Chemistry and Drug
Discovery sixth edition volume 1 edited by
Donald J. Abraham.
• Bioisosteres in Medicinal Chemistry, First
Edition. Edited by Nathan Brown 2012 Wiley-
VCH Verlag GmbH & Co. KGaA. Published 2012
by Wiley-VCH Verlag GmbH & Co. KGaA.

45. 45
THANK YOU